Oncology On The Go

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
As part of its Between the Lines™ video series, CancerNetwork® spoke with Paul G. Richardson, MD, clinical program leader and director of Clinical Research for the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, Massachusetts, and Christina Gasparetto, MD, professor of medicine at Duke University Medical School in Durham, North Carolina, about recent updates in the use of proteasome inhibitors for patients with multiple myeloma.
In the video series, Richardson and Gasparetto discussed the following:
·      Overview of proteasome inhibitor therapy in multiple myeloma

·      Real-world data with proteasome inhibitors

·      The phase 3 TOURMALINE-MM1 trial (NCT01564537) of ixazomib therapy in relapsed/refractory multiple myeloma

·      Ixazomib plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

Be sure to tune in to other videos in the CancerNetwork® Between the Lines™ series.

This week, CancerNetwork looks at the final part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, concludes his conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine.
This conversation focuses on resistance to targeted therapies in metastatic colorectal cancer, and the importance of addressing it. The experts also discuss EGFR resistance, EGFR rechallenging after prior progression, and rising HER2 amplification.
Thanks for tuning in to this series on colorectal cancer from CancerNetwork. Visit cancernetwork.com to catch up on any episodes you missed and to read more about these topics published in the journal ONCOLOGY.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork turns to the second part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, continues the conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine.
This episode’s discussion turns to the GOZILA platform and its international collaboration. The experts expand on this platform, what it means for drug development, and examine genetic testing in GI malignancies.
Tune in next week for the third and final part of this conversation on colorectal cancer.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork kicks off the first of a 3-part podcast series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, leads a conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University School of Medicine.
This conversation focuses on the current molecular treatment landscape of advanced colorectal cancer and the need for the COLOMATE platform. Among other things, the experts detail this platform and expand on its impact for patients, as well as the evolving world of colorectal cancer.
Make sure to tune in next week for part 2 of this conversation on colorectal cancer.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ program, CancerNetwork hosted a discussion Lori Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital in Boston, who shared her perspective on updates in the treatment of second-line radioiodine-refractory differentiated thyroid cancer, or DTC.
In the video series, some of the content discussed included:·      Presentation and Disease Course of Differentiated Thyroid Cancer

·      Frontline Treatment Options for RAI-refractory DTC

·      Treatment Options in RAI-refractory DTC in Second Line and Beyond

·      Facing Unmet Needs and Ongoing Trials in RR-DTC

To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview. 
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with David H. Aggen, MD, PhD, of the Memorial Sloan Kettering Cancer Center, Robert S. Alter, MD, of the John Theurer Cancer Center, Arnab Basu, MD, MPH, of the O’Neal Comprehensive Cancer Center, Mehmet Asim Bilen, MD, of Winship Cancer Institute, and Chung-Han Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, who shared their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and commented on emerging data in the field.

To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview. 

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available. 

OncView™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC
 
As part of its OncView™ video series, CancerNetwork® spoke with Gregory Riely, MD, PhD, vice chair of Clinical Research in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, and Tarek Mekhail, MD, a hematologic oncologist from Advent Health in Florida, about patients with EGFR exon 20 insertion-positive metastatic non–small cell lung cancer who recieved mobocertinib.  
 
In the video series, Gregory Riely, MD, PhD, and Tarek Mekhail, MD, discussed the following: 

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview. 

This week, CancerNetwork® spoke with Christine Chung, DO, of the Swedish Medical Center, Englewood, Colorado, about “Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma,” a retrospective review published in the journal ONCOLOGY.
Chung detailed this research, which characterizes the mutational landscape of patients with metastatic pancreatic adenocarcinoma who received blood-based molecular profiling. A total of 77 consecutive patients were included in the analysis.
Chung also spoke about pancreatic adenocarcinoma, the study’s main findings, and how this research can inform future treatment decision-making processes moving forward.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork® spoke with Muhammad Niazi, MD, resident in internal medicine at Staten Island University Hospital, and Alexander Bershadskiy, MD, attending physician at Staten Island University Hospital, about a meta-analysis published in ONCOLOGY titled, “Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.”
The final analysis evaluated 3 randomized clinical trials. A fixed model showed a statistically significant improvement in overall survival for patients with metastatic castration-resistant prostate cancer treated with PARP inhibitors.
The authors provided a detailed background on PARP inhibitors and further detailed the results of this research, focusing on survival increases with PARP inhibitor treatment for this patient population.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.
In the video series, Piotrowska discussed the following:
·      Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions

·      Testing for the EGFR Exon 20 Insertion

·      Historical Treatment Approach for EGFR Exon 20 Insertions in NSCLC

·      Amivantamab for the Treatment of EGFR Exon 20 Insertions in NSCLC

·      Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC

·      Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC

·      Unmet Needs and Future Directions

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.